familial chylomicronaemia syndrome
Arrowhead’s RNAi therapeutic plozasiran shows promise in familial chylomicronaemia syndrome
There are currently no therapies in the US specifically approved to treat the rare genetic disorder
Ionis shares positive late-stage results for olezarsen in familial chylomicronaemia syndrome
The rare genetic disease is estimated to affect up to 13 people per million in the US
GSK to acquire exclusive rights to Janssen’s hepatitis B therapy in $1bn deal
GSK will evaluate the therapy in combination with its own hepatitis B treatment